Expert perspectives on the emerging role of navitoclax, a novel BCL-XL inhibitor, in the treatment armamentarium for myelofibrosis and T-cell acute lymphoblastic leukemia, respectively.
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
2 Commerce Drive
Cranbury, NJ 08512